Literature DB >> 34570274

Variation of homocysteine levels in rheumatoid arthritis patients: relationship to inflammation, cardiovascular risk factors, and methotrexate.

Rawdha Tekaya1,2, Leila Rouached3,4, Habib Ben Ahmed1,5, Aicha Ben Tekaya1,2, Selma Bouden1,2, Olfa Saidane1,2, Kahena Bouzid1,6, Ines Mahmoud1,2, Leila Abdelmoula1,2.   

Abstract

BACKGROUND: The aim of this study was to evaluate the variation of homocysteine (Hcy) levels in patients with rheumatoid arthritis (RA) and to analyze the relationship to inflammatory parameters, cardiovascular risk, and methotrexate (MTX).
METHODS: This cross-sectional study assessed disease activity and treatment in RA patients. The European League Against Rheumatism (EULAR) 2015 HeartSCORE was performed for cardiovascular (CV) risk estimation and levels of plasma Hcy, serum folate concentrations, vitamin B12, and erythrocyte sedimentation rate (ESR) were measured.
RESULTS: A total of 103 participants with mean age 53 ± 10 years and mean disease duration 10.55 ± 7.34 years were included. Patients were treated with MTX in 69.9% of cases and corticosteroid in 80.5% of cases. Of all patients, 13% had a cardiovascular inheritance, 25% were hypertensive, and 18% had diabetes. The EULAR 2015 HeartSCORE was high and very high (≥5%) in 35% of cases. Mean Hcy level was 12.54 ± 4.2 µmol/L [6.89-32.92] and hyperhomocysteinemia was noted in 20.4% of patients. Analytic study demonstrated that hyperhomocysteinemia was associated with male gender (p = 0.01), MTX use (p = 0.01), smoking (p = 0.008), renal failure (p = 0.04), and high disease activity (p = 0.05), but there was no association with the HeartSCORE (p = 0.23). Hcy level was negatively correlated with folate (p = 0.009) and vitamin B12 level (p = 0.02) and positively with age (p = 0.01), C‑reactive protein (CRP; p = 0.05), and Simplified Disease Activity Index (SDAI; p = 0.03). In multivariate logistic regression analysis, current MTX use, levels of vitamin B12 and creatine, and Clinical Disease Activity Index (CDAI) appeared to be independent factors associated with hyperhomocysteinemia.
CONCLUSION: MTX use, CDAI, and the levels of vitamin B12 and creatine are independent factors associated with hyperhomocysteinemia.
© 2021. Springer Medizin Verlag GmbH, ein Teil von Springer Nature.

Entities:  

Keywords:  Autoimmune diseases; Cardiovascular disease; Disease-modifying anti-rheumatic drugs; Hyperhomocysteinemia; Inflammation

Year:  2021        PMID: 34570274     DOI: 10.1007/s00393-021-01092-2

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  8 in total

1.  Serum homocysteine and methylmalonic acid in patients with rheumatoid arthritis and cobalaminopenia.

Authors:  T Pettersson; C Friman; L Abrahamsson; B Nilsson; B Norberg
Journal:  J Rheumatol       Date:  1998-05       Impact factor: 4.666

2.  Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

Authors:  S Wallberg-Jonsson; M L Ohman; S R Dahlqvist
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

3.  Homocysteine and antiphospholipid antibodies in rheumatoid arthritis patients: relationships with thrombotic events.

Authors:  B Seriolo; D Fasciolo; A Sulli; M Cutolo
Journal:  Clin Exp Rheumatol       Date:  2001 Sep-Oct       Impact factor: 4.473

4.  Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.

Authors:  S L Morgan; J E Baggott; J Y Lee; G S Alarcón
Journal:  J Rheumatol       Date:  1998-03       Impact factor: 4.666

Review 5.  Homocysteine and cardiovascular disease.

Authors:  H Refsum; P M Ueland; O Nygård; S E Vollset
Journal:  Annu Rev Med       Date:  1998       Impact factor: 13.739

6.  Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis.

Authors:  Solveig Wållberg-Jonsson; Jasmina Trifunovic Cvetkovic; Karl-Gösta Sundqvist; Ann Kari Lefvert; Solbritt Rantapää-Dahlqvist
Journal:  J Rheumatol       Date:  2002-05       Impact factor: 4.666

7.  Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study.

Authors:  O Nygård; S E Vollset; H Refsum; I Stensvold; A Tverdal; J E Nordrehaug; M Ueland; G Kvåle
Journal:  JAMA       Date:  1995-11-15       Impact factor: 56.272

8.  Atherothrombotic events in rheumatoid arthritis are predicted by homocysteine - a six-year follow-up study.

Authors:  S Berglund; A Södergren; S Wållberg Jonsson; S Rantapää Dahlqvist
Journal:  Clin Exp Rheumatol       Date:  2009 Sep-Oct       Impact factor: 4.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.